Switzerland-based pharmaceutical company Novartis (NYSE: NVS) has announced additional results from an ongoing Phase III study evaluating the CDK4/6 inhibitor Kisqali (ribociclib) in combination with endocrine therapy for stage II and III HR+/HER2- early breast cancer (EBC). The findings confirm that the combination therapy significantly improves invasive disease-free survival (iDFS) across various subgroups compared to endocrine therapy alone.
Study Findings and Risk Reduction
The study demonstrated a notable decrease in the risk of recurrence, ranging from 20% to 37% across different subgroups based on tumor stage, nodal involvement, menopausal status, and age. These results were observed after a median follow-up period of 27.7 months, highlighting the therapy’s potential to enhance outcomes for patients with early-stage breast cancer.
Implications for Treatment and Future Research
These positive results underscore the importance of Kisqali as a valuable addition to the treatment landscape for HR+/HER2- early breast cancer. Novartis continues to advance its research and development efforts to provide innovative solutions that address unmet medical needs and improve patient outcomes.-Fineline Info & Tech
